Nanoparticle News and Research

RSS

In nanotechnology, a particle is defined as a small object that behaves as a whole unit in terms of its transport and properties. It is further classified according to size: in terms of diameter, fine particles cover a range between 100 and 2500 nanometers, while ultrafine particles, on the other hand, are sized between 1 and 100 nanometers.

Striking difference identified between mRNA vaccination vs. SARS-CoV-2 infection immune responses

A team of scientists from the United States has recently compared the immune response elicited by natural severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease 2019 (COVID-19) vaccination. Their findings reveal that, unlike vaccination, natural SARS-CoV-2 infection is associated with a robust interferon response together with an induction of cytotoxic gene expression in peripheral blood lymphocytes. The study is currently available on the medRxiv* preprint server.

22 Apr 2021

Developing nanoparticles to detect and kill multi-resistant pathogens

Multi-resistant pathogens are a serious and increasing problem in today's medicine. Where antibiotics are ineffective, these bacteria can cause life-threatening infections.

22 Apr 2021

Argonne's Advanced Photon Source guided the development of new COVID-19 vaccine now in trials

Human clinical trials have begun on a new vaccine candidate that may protect against not only SARS-CoV-2, the virus that causes COVID-19, but against at least two of the variants emerging around the world.

21 Apr 2021

Interfering RNA nanoparticles could be a potential COVID-19 therapy

Study shows lipid nanoparticle-based siRNA is potent in suppressing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the causative agent of coronavirus disease 2019 (COVID-19) – in cells as well as in mice models.

21 Apr 2021

Can fingerprick blood tests help evaluate antibody response and longevity against SARS-CoV-2 post-vaccination?

To monitor antibody level duration of vaccine-induced immune responses, a team of researchers in the U.S. – at Diacarta, University of California and VA Healthcare System, and the Franciscan University of Steubenville – evaluated the feasibility of using a single drop of fingerstick blood collected with flocked swabs for quantitative antibody response evaluation after COVID-19 vaccination.

20 Apr 2021

Novel mRNA delivery vehicle provides alternative to LNPs for SARS-CoV-2 vaccines

Researchers in the United States have developed an alternative messenger RNA (mRNA) delivery platform to the lipid nanoparticles that are currently used in vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

18 Apr 2021

Curcumin nanosystems could be powerful COVID-19 therapeutics

With new variants of SARS-CoV-2 emerging, the COVID-19 pandemic is far from over. While the global vaccine rollout has moved at an impressive speed, the search for new safe, effective, and targeted therapies is still on. Now, a new study reviews the potential for curcumin, a natural alkaloid derived from turmeric, and nanosystems to treat COVID-19.

16 Apr 2021

Repurposing an existing, cheap drug into long-acting injectable therapy to treat Covid-19

Researchers from the University of Liverpool have shown the potential of repurposing an existing and cheap drug into a long-acting injectable therapy that could be used to treat Covid-19.

16 Apr 2021

Highly Accurate Physicochemical Characterisation of Small Nanoparticles

Analytik Ltd reports how researchers at the Centre for Bionano Interactions, University College Dublin, Ireland have used a DC24000 ultra high-resolution particle size analyzer for accurate physicochemical characterisation of small-sized nanoparticles.

From Analytik Ltd 15 Apr 2021

New research could help solve major challenge in the deployment of COVID-19 vaccines

New research by University of Texas at Dallas scientists could help solve a major challenge in the deployment of certain COVID-19 vaccines worldwide -- the need for the vaccines to be kept at below-freezing temperatures during transport and storage.

15 Apr 2021

A new polymersome-based SARS-CoV-2 nanovaccine elicits robust immunity

As newer vaccines are being developed to combat the ongoing pandemic of coronavirus disease 2019 (COVID-19), targeting the pathogen, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a new preprint research paper posted to the bioRxiv server describes a new subunit nanovaccine that appears to have robust immunogenicity and neutralizing activity.

14 Apr 2021

Researchers develop broad-spectrum SARS-CoV-2 RBD-based vaccine

In a recent bioRxiv* preprint, the large team of researchers evaluated a SARS-CoV-2 Spike receptor-binding domain ferritin nanoparticle protein vaccine (RFN) in a nonhuman primate challenge model. This study addresses the need for a next-generation, efficacious vaccine with an increased pan-SARS breadth of coverage.

13 Apr 2021

Moderna COVID-19 vaccine ensures long-term protection against SARS-CoV-2 infection, suggests study

A recent report published in the New England Journal of Medicine has revealed that the COVID-19 vaccine developed by Moderna, Inc, USA, is capable of inducing robust and durable antibody responses for at least six months post-vaccination.

8 Apr 2021

Implantable sensor based on gold nanoparticles revolutionizes medical diagnostics

The idea of implantable sensors that continuously transmit information on vital values and concentrations of substances or drugs in the body has fascinated physicians and scientists for a long time. Such sensors enable the constant monitoring of disease progression and therapeutic success.

6 Apr 2021

Novel hydrogel-based vaccine formulation shows high efficacy against SARS-CoV-2

A fascinating new preprint research paper posted to the bioRxiv* server discusses impressively high neutralizing responses elicited with a single dose of a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine formulation, which could help turn the tide of the current pandemic if validated.

6 Apr 2021

New nanoparticle SARS-CoV-2 vaccine confers robust protection with single dose after two weeks

In a methodologically ‘state-of-the-art’ approach, US researchers have developed a protein-based nanoparticle vaccine against coronavirus disease (COVID-19), with a swift generation of antibodies and the potential to protect individuals who cannot receive other COVID-19 vaccines for medical reasons. The research is posted to the bioRxiv* preprint server.

5 Apr 2021

Phase 1 clinical study of unique vaccine to protect against COVID-19 begins

A unique vaccine to protect against COVID-19 begins clinical testing Tuesday, 6 April, at the Walter Reed Army Institute of Research (WRAIR), part of the U.S. Army Medical Research and Development Command.

5 Apr 2021

New mRNA COVID-19 vaccine candidate shows promise in vivo

Researchers report that a new lipid nanoparticle mRNA coronavirus disease 2019 (COVID-19) vaccine candidate protected 70% of mice expressing the human angiotensin-converting enzyme 2 (ACE2), while all the non-vaccinated mice died.

31 Mar 2021

Development of a model of substrate coordination to Zn-bound ACE2

The ongoing coronavirus disease-19 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has claimed more than 2.8 million lives worldwide. Authorities are facing difficulty in preventing the spread of disease due to the highly infectious nature of SARS-CoV-2. Therefore, reducing the virus's ability to infect an individual's respiratory epithelial cells could prove an effective measure to prevent disease transmission.

31 Mar 2021

Researchers develop broadly neutralizing SARS-CoV-2 ferritin nanoparticle vaccine

In the continued need for next-generation vaccines that confer broad protection against COVID-19, scientists developed an adjuvanted SARS-CoV-2 Spike Ferritin Nanoparticle (SpFN) vaccine.

30 Mar 2021

Nanoparticle News and Research

Further Reading

Striking difference identified between mRNA vaccination vs. SARS-CoV-2 infection immune responses

Developing nanoparticles to detect and kill multi-resistant pathogens

Argonne's Advanced Photon Source guided the development of new COVID-19 vaccine now in trials

Interfering RNA nanoparticles could be a potential COVID-19 therapy

Can fingerprick blood tests help evaluate antibody response and longevity against SARS-CoV-2 post-vaccination?

Novel mRNA delivery vehicle provides alternative to LNPs for SARS-CoV-2 vaccines

Curcumin nanosystems could be powerful COVID-19 therapeutics

Repurposing an existing, cheap drug into long-acting injectable therapy to treat Covid-19

Highly Accurate Physicochemical Characterisation of Small Nanoparticles

New research could help solve major challenge in the deployment of COVID-19 vaccines

A new polymersome-based SARS-CoV-2 nanovaccine elicits robust immunity

Researchers develop broad-spectrum SARS-CoV-2 RBD-based vaccine

Moderna COVID-19 vaccine ensures long-term protection against SARS-CoV-2 infection, suggests study

Implantable sensor based on gold nanoparticles revolutionizes medical diagnostics

Novel hydrogel-based vaccine formulation shows high efficacy against SARS-CoV-2

New nanoparticle SARS-CoV-2 vaccine confers robust protection with single dose after two weeks

Phase 1 clinical study of unique vaccine to protect against COVID-19 begins

New mRNA COVID-19 vaccine candidate shows promise in vivo

Development of a model of substrate coordination to Zn-bound ACE2

Researchers develop broadly neutralizing SARS-CoV-2 ferritin nanoparticle vaccine

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo